2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Bispecific Antibody Therapy, Non-Biological Therapies, Adverse Events, Clinical Practice (Health Services and Quality), Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

1634 A phase 1b study of the triplet combination of  iadademstat in combination with azacitidine and venetoclax for newly diagnosed acute myeloid leukemia

Curtis Lachowiez, MD, Andy Kaempf, MS2, Carolyn Lehn3, Tara Lundberg, BA4, Gabriella Sheldon5, Anna Regina Samson6, Jessica Maria Stempel, MD, MHS7, Jessica Leonard I, M.D.8, Gabrielle Meyers, MD9, Arpita Gandhi, M.D., M.S.10, Jennifer Saultz, DO11, Rachel Cook, M.D.12, Gordon Mills, MD, PhD13, Ronan Swords, MD14, Theodore Paul Braun, MD PhD15
1 Oregon Health & Science University, Portland, Oregon, United States
2 Oregon Health & Science University, Portland, Oregon, United States
3 Oregon Health & Science University, Portland, Oregon, United States
4 Oregon Health & Science University, Portland, Oregon, United States
5 Oregon Health & Science University, Portland, Oregon, United States
6 Oregon Health & Science University, Portland, Oregon, United States
7 Oregon Health & Science University, Portland, Oregon, United States
8 Oregon Health & Science University, Portland, Oregon, United States
9 Oregon Health & Science University, Portland, Oregon, United States
10 Oregon Health & Science University, Portland, Oregon, United States
11 Oregon Health & Science University, Portland, Oregon, United States
12 Oregon Health & Science University, Portland, Oregon, United States
13 Oregon Health & Science University, Portland, Oregon, United States
14 Oregon Health & Science University, Portland, Oregon, United States
15 Oregon Health & Science University, Portland, Oregon, United States

Background:

Azacitidine plus venetoclax (AZA+VEN) is standard of care for older and/or unfit patients (pts) with newly diagnosed acute myeloid leukemia (ND-AML) and an emerging option for fit pts; however, relapse is common, particularly in those without targetable molecular alterations. Iadademstat (IADA), an oral lysine-specific demethylase-1 (LSD1) inhibitor, has demonstrated encouraging activity in combination with AZA, including MRD negativity rates and activity in AML with mutations conferring resistance to AZA+VEN. Herein, we report results from an ongoing Phase Ib study evaluating IADA combined with AZA+VEN in ND-AML (NCT06357182).

Methods:

Patients aged ≥18 years with ELN 2022 intermediate- or adverse-risk AML (or MDS/AML) were eligible. Four dose levels (DL1: 100 mcg IADA; DL2: 150 mcg IADA; two de-escalation levels) were evaluated using a backfilling Bayesian optimal interval (BF-BOIN) design and 20% target DLT rate. IADA was administered orally on Days 1–5, 8–12, and 15–19 of 28-day cycles with AZA (75 mg/m² Days 1–7) and VEN (400 mg Days 1–21).

The primary objective was determination of the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). Secondary objectives were to assess efficacy including composite complete remission (CRc; CR + CRh + CRi) rate and overall response rate (ORR; CRc + MLFS + PR), and safety via incidence of grade (Gr) ≥3 treatment-emergent adverse events (TEAEs). Exploratory endpoints included survival outcomes (estimated with Kaplan-Meier) and PD biomarkers. Analysis populations consisted of MTD-evaluable (≥75% cycle 1 dose exposure), safety (any IADA exposure), and efficacy (study drug triplet exposure and at least 1 post-baseline disease assessment) pt sets.

Results:

As of July 2026, 22 pts had enrolled, with target enrollment of 21 MTD-evaluable pts in the dose-escalation component of BF-BOIN nearly met (3 pts enrolled as backfills). Of these 22 pts, 6 were assigned to DL1 and 16 to DL2. Median age was 71 years (range, 30–81), 68% were male, 82% ELN 2022 adverse risk, and 23% had secondary AML. PRISM-3 risk was low, moderate, and high in 55%, 27%, and 18%, respectively.

In MTD-evaluable pts (n=19), 4 DLTs occurred (in 3 pts, all in DL2): two cases of prolonged Gr4 neutropenia, one Gr4 differentiation syndrome (DS), and one Gr4 C. difficile colitis. The DS resolved with corticosteroids and supportive care. Thus, current DLT rates were 0% for DL1 and 20% for DL2. No treatment-related deaths occurred.

In safety set pts (n=22), the most common Gr 1–2 TEAEs were constipation (63%), rash (59%), and nausea (50%). Gr ≥3 TEAEs occurring in >1 pt included febrile neutropenia (36%), neutropenia (31%), thrombocytopenia (31%), acute kidney injury (9%), and elevated liver function tests (9%). One pt had Gr 3 tumor lysis syndrome, which resolved in 3 days with medical management. Thirty- and 60-day mortality were both 5%. LSD1 target engagement was attained in 85% (N=3) of DL1  and 90% (n=8) of DL2 pts.

In efficacy-evaluable pts to date (n=19), the ORR was 95%, including CR in 74% and CRc in 84%. Two pts achieved morphologic leukemia-free state, and one pt, with TP53-mutated acute erythroid leukemia, did not respond. Two additional pts with TP53-mutated AML both attained CR, with TP53 variant allele frequency reduction or clearance noted in remission. 

In responding pts, median time to absolute neutrophil count recovery (≥500 cells/μL) and platelet count recovery (≥50,000 cells/μL) was 32 days during cycle 1 and 37 days during cycle 2, with no significant differences between dose levels. Median time to best response was one cycle (range, 1–2). Ten pts proceeded to allogeneic hematopoietic cell transplantation.

After median follow-up of 8 months, 12-month overall survival (OS) was 76%. Median OS was not reached in pts with ELN 2022 intermediate- or adverse-risk disease (12-month OS rates of 100% and 74%, respectively).  One-year OS by PRISM-AML was 82%, 75%, and 50% for low-, moderate-, and high-risk groups, respectively. In pts with sAML (n=5), 12-month OS was 100%.

Conclusions:

Iadademstat combined with AZA+VEN has demonstrated a manageable safety profile with encouraging efficacy in ND-AML. High remission rates, rapid responses, acceptable hematologic recovery, and encouraging early survival support continued evaluation of this novel triplet regimen. Presentation of completed enrollment and MTD and/or RP2D is planned in addition to further safety, efficacy, PD, and other correlative results.

Curtis Lachowiez, MD: AbbVie - Research Funding; COTA, Inc. - Consultancy (Includes expert testimony); Syndax - Consultancy (Includes expert testimony); Servier - Consultancy (Includes expert testimony); Abbvie/Genentech - Consultancy (Includes expert testimony); Astellas Pharma - Consultancy (Includes expert testimony); Rigel - Consultancy (Includes expert testimony)